

## AUSTRALIAN PATENT GRANTED FOR SUBB2M TECHNOLOGY

- AU Patent No 2017358401 granted covering the SubB2M technology
- Provides IP protection in Australia for SubB2M-based diagnostics

**Melbourne, Australia, 3 May 2022:** INOVIQ Limited (ASX:IIQ) (**INOVIQ** or the **Company**) announces that Australian Patent No 2017358401 entitled “*Subtilase cytotoxin B subunit mutant*” was issued by IP Australia to Griffith University and the University of Adelaide. The patent covers the SubB2M technology and INOVIQ Ltd holds the exclusive worldwide rights to the SubB2M intellectual property for diagnostic applications.

CEO Dr Leeearne Hinch said: “*This patent enforces intellectual property protection in Australia for INOVIQ’s SubB2M-based diagnostics pipeline for monitoring of breast and ovarian cancers. This is the first patent granted for the SubB2M technology patent family.*”

Australian patent 2017358401 is due to expire on 9 November 2037 and claims modified SubB proteins capable of binding N-glycolylneuraminic acid (Neu5Gc) and variants and fragments thereof, such as SubB2M.

### SubB2M technology and recent milestones


The SubB2M technology is based on an engineered protein that specifically detects the pan-cancer biomarker Neu5Gc that is found in multiple human cancers including breast, ovarian, prostate and others.

INOVIQ’s SubB2M diagnostics pipeline includes SubB2M-based immunoassays for monitoring of breast and ovarian cancers, and a SubB2M-based surface plasmon resonance (SPR) test for the detection of Neu5Gc levels in a general health panel.

The granting of this Australian patent is another important step in INOVIQ’s path to commercialisation for its SubB2M-based tests and follows other recent key milestones. These include the signing of a Master Services Agreement with US-based contract diagnostics organisation ResearchDx for the development and validation of its SubB2M-based tests in the USA (ASX: 5 April 2022), and a Master Manufacturing Agreement with MP Biomedicals Asia Pacific Pte Ltd for the provision of contract manufacturing services to produce the SubB2M protein to cGMP standard (ASX: 5 April 2022).

### SubB2M diagnostics pipeline next steps

The SubB2M diagnostics pipeline is now undergoing further feasibility testing, development, and validation at US-based contract diagnostic organisation, ResearchDx. The development plan is as follows:



Authorised by the Company Secretary, Tony Di Pietro.

- ENDS -

## COMPANY CONTACTS

**Dr Leearne Hinch**  
Chief Executive Officer  
E [lhinch@inoviq.com](mailto:lhinch@inoviq.com)  
M +61 400 414 416

**Dr Geoff Cumming**  
Non-Executive Chairman  
E [geoff.cumming@inoviq.com](mailto:geoff.cumming@inoviq.com)  
M +61 417 203 021

**Jane Lowe**  
IR Department  
E [jane.lowe@irdepartment.com.au](mailto:jane.lowe@irdepartment.com.au)  
M +61 411 117 774

## ABOUT INOVIQ LTD

INOVIQ Ltd (ASX:IIQ) (**INOVIQ**) is developing and commercialising innovative diagnostic and exosome-based products to improve the diagnosis and treatment of cancer and other diseases. The Company has commercialised the hTERT test used as an adjunct to urine cytology testing for bladder cancer and the EXO-NET pan-exosome capture tool for research purposes. Our cancer diagnostic pipeline includes blood tests in development for earlier detection and monitoring of ovarian, breast, prostate, and other cancers. For more information on INOVIQ, see [www.inoviq.com](http://www.inoviq.com).

## FORWARD LOOKING STATEMENTS

This announcement contains certain 'forward-looking statements' within the meaning of the securities laws of applicable jurisdictions. Forward-looking statements can generally be identified by the use of forward-looking words such as 'may', 'should', 'expect', 'anticipate', 'estimate', 'scheduled' or 'continue' or the negative version of them or comparable terminology. Any forecasts or other forward-looking statements contained in this announcement are subject to known and unknown risks and uncertainties and may involve significant elements of subjective judgment and assumptions as to future events which may or may not be correct. There are usually differences between forecast and actual results because events and actual circumstances frequently do not occur as forecast and these differences may be material. The Company does not give any representation, assurance or guarantee that the occurrence of the events expressed or implied in any forward-looking statements in this announcement will actually occur and you are cautioned not to place undue reliance on forward-looking statements.